Investment
Features
FeesSafety
Academy
More
Pluang+

Tech stocks dominated September's S&P 500 winners, led by Everpure's 40.7% gain.

Market News
03 Oct 2026
Seeking Alpha
View Source
Neutral
Tech stocks dominated September's S&P 500 winners, led by Everpure's 40.7% gain.

In September, technology stocks led the S&P 500's best performers, with 13 of the top 20 winners coming from the sector. Everpure topped the list with a 40.7% gain, followed by Moderna, Intel, and Bloom Energy, each rising over 30%. On the downside, Fair Isaac saw a steep decline of 48.36%, and Gen Digital dropped nearly 29%. This highlights the strong tech sector momentum amid broader market volatility.

September's tech sector surge is still visible in early October trading. On Pluang as of Oct 03, 2026 11:41 WIB, Moderna (MRNA) trades at USD 190.01, up 0.57% for the day, while Intel (INTC) is slightly down 0.56% at USD 119.33. Bloom Energy (BE) shows stronger momentum with a 4.17% gain, priced at USD 289.15, reflecting ongoing interest in these leading tech and industrial stocks.

More News (MRNA)

Nike sales drop 4% with China revenue down 22%, Moderna joins Nasdaq-100, mortgage credit reporting rules may change.

Nike sales drop 4% with China revenue down 22%, Moderna joins Nasdaq-100, mortgage credit reporting rules may change.

Nike reported a 4% decline in Q1 sales, driven by a 22% drop in China revenue, impacting its overall performance and leading to a 9% premarket share decline. Moderna will replace Warner Bros Discovery in the Nasdaq-100, reflecting its strong market p...

Market News
Bearish
22 hours ago
Moderna stock rises 3% despite Citigroup downgrade over valuation concerns

Moderna stock rises 3% despite Citigroup downgrade over valuation concerns

Moderna shares climbed 3% even after Citigroup downgraded the stock to Sell, citing high valuation following a 222% rise since positive melanoma vaccine trial results. The market seems optimistic about Moderna's personalized cancer vaccine pipeline, ...

Market News
Bullish
1 day ago
Moderna stock drops 6% after Citi downgrades it over cancer vaccine valuation concerns

Moderna stock drops 6% after Citi downgrades it over cancer vaccine valuation concerns

Citigroup downgraded Moderna from Hold to Sell, citing that the stock's recent surge is not supported by its current cancer vaccine pipeline. Despite a 590% rise in 2026, Citi's analyst raised the price target to $80, still well below Moderna's tradi...

Market News
Bearish
2 days ago
Navitas Semiconductor jumps 12% after winning U.S. Army contract for advanced silicon carbide tech

Navitas Semiconductor jumps 12% after winning U.S. Army contract for advanced silicon carbide tech

Navitas Semiconductor's shares rose 12% premarket after securing a U.S. Army contract to develop next-generation silicon carbide power semiconductor technology. This project aims to create a domestic manufacturing process for ultra-high-voltage silic...

Market News
Bullish
3 days ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App